- Home
- TMCI vs IPHA Comparison
TMCI vs IPHA Comparison
Compare TMCI & IPHA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | TMCI | IPHA |
|---|---|---|
| Founded | 2014 | 1999 |
| Country | United States | France |
| Employees | N/A | 174 |
| Industry | Biotechnology: Electromedical & Electrotherapeutic Apparatus | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 120.4M | 119.1M |
| IPO Year | 2021 | N/A |
Fundamental Metrics
Financial Performance| Metric | TMCI | IPHA |
|---|---|---|
| Price | $1.19 | $1.25 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 6 | 4 |
| Target Price | $4.77 | ★ $5.75 |
| AVG Volume (30 Days) | ★ 783.3K | 17.6K |
| Earning Date | 05-07-2026 | 03-26-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $212,690,000.00 | N/A |
| Revenue This Year | N/A | $181.17 |
| Revenue Next Year | $7.65 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 1.59 | N/A |
| 52 Week Low | $1.19 | $1.18 |
| 52 Week High | $8.56 | $2.63 |
Technical Indicators
Market Signals| Indicator | TMCI | IPHA |
|---|---|---|
| Relative Strength Index (RSI) | 30.44 | 37.82 |
| Support Level | N/A | $1.18 |
| Resistance Level | $3.01 | $1.88 |
| Average True Range (ATR) | 0.10 | 0.09 |
| MACD | 0.01 | -0.01 |
| Stochastic Oscillator | 1.52 | 28.43 |
Price Performance
Historical ComparisonAbout TMCI Treace Medical Concepts Inc.
Treace Medical Concepts Inc is a commercial-stage orthopaedic medical device company. It is focused on advancing the standard of care for the surgical management of bunion deformities. The company's patented Lapiplasty 3D Bunion Correction procedure is designed to reproducibly correct all planes of the bunion deformity and address the root cause of the bunion, while allowing patients to return to their active lives quickly. The Company operates and manages its business as one segment, which is the business of designing, manufacturing, and marketing medical devices for physicians, surgeons, ambulatory surgery centers and hospitals.
About IPHA Innate Pharma S.A. ADS
Innate Pharma SA is a clinical-stage biotechnology company. It is engaged in developing immunotherapies for cancer patients. Its approach is to harness the innate immune system through therapeutic antibodies and its ANKET (Antibody-based NK cell Engager Therapeutics) proprietary platform. The company's revenue results from payments received to research, collaboration, and licensing agreements signed with pharmaceutical companies. Its product pipeline includes lacutamab, monalizumab, IPH5201, IPH5301, IPH6101, IPH62, IPH6401 and IPH6501.